Medical treatment

Overseas medical treatment in trouble again with Omicron surge – Magnetic Media

By Dana Malcolm

Personal editor

February 16, 2022 – Johnson & Johnson has officially halted production at all of its Covid-19 vaccine production facilities; It comes after last week’s announcement that some production would be halted for the pharmaceutical company to focus on a new vaccine, unrelated to Covid-19.

The move comes as vaccination slows in high-income countries, especially those in Europe, and they begin rolling back Covid-19 restrictions.

Johnson & Johnson said: “We are dedicated to improving human health and have worked tirelessly to…build a global manufacturing network on four continents to produce our COVID-19 vaccine. Our manufacturing sites manufacture multiple products because we have an obligation to deliver life-changing medicines to patients around the world and to advance our innovative pipeline of new medicines and vaccines. We are managing our production planning accordingly and are currently sourcing from our extensive global network based on the demand for our vaccine and the needs of our patients and customers. »

The pharmaceutical company announced on February 8 that the factory would temporarily cease COVID19 operations to work on another vaccine against a different virus, The New York Times reports.

The move sparked immediate fears from organizations like COVAX and the African Union that depend on the Johnson & Johnson vaccine to meet their quotas and distribute the vaccines to poorer countries around the world.

Despite the controversy surrounding the vaccine and its effects on blood clotting, Johnson & Johnson is one of the most widely distributed brands in the world.

The company said it provides according to patient and customer needs, but so far only 54% of the world’s population has been fully vaccinated against COVID-19. Of note is the staggering inequality of vaccination: only 11% of the population has received a dose of vaccine in low-income countries. Conversely, high-income countries have succeeded in vaccinating more than 78% of their population.

Johnson & Johnson is currently used in 82 different countries around the world.

It raises the question of why Johnson & Johnson is stopping production when there are so many people in low-income countries, especially still dependent on its vaccine.

The NY Times also reports that neither COVAX nor the African Union were informed of Johnson & Johnson’s decision beforehand.

The African Union said: “Now is not the time to change the production line of anything, when the lives of people in the developing world are at stake.”

COVAX expressed similar sentiments. They said Johnson & Johnson had already let them down in 2021 and they couldn’t say they would be disappointed in 2022.

In response, J&J said, “We are working to ensure our vaccine is available where people need it, and we continue to fulfill our contractual obligations in relation to the COVAX facility and the African Union, we currently have millions of doses of our COVID-19 vaccine in stock.

Johnson & Johnson has struggled with vaccines expiring before they can be used early in production. The FDA extended the expiration dates in July of last year from the original four and a half months.

Vaccines currently have a shelf life of six months.